Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.
Dextromethorphan was granted FDA approval before 3 December 1957.
Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicat...
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India
UAB Beacon Tower, Birmingham, Alabama, United States
Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Toronto Western Hospital, Toronto, Ontario, Canada
Stanford University, Stanford, California, United States
Goshen Health, Goshen, Indiana, United States
MultiCare Health System, Tacoma, Washington, United States
NEXT Oncology, Fairfax, Virginia, United States
Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Volunteer recruitment center Covance Leeds Covance Leeds, Leeds, United Kingdom
Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, United States
Johns Hopkins Department of Psychiatry, Baltimore, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.